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Abstract
Objective: To optimally leverage the scalability and unique features of the electronic health records (EHR) for research that
would ultimately improve patient care, we need to accurately identify patients and extract clinically meaningful measures.
Using multiple sclerosis (MS) as a proof of principle, we showcased how to leverage routinely collected EHR data to identify
patients with a complex neurological disorder and derive an important surrogate measure of disease severity heretofore
only available in research settings.
Methods: In a cross-sectional observational study, 5,495 MS patients were identified from the EHR systems of two major
referral hospitals using an algorithm that includes codified and narrative information extracted using natural language
processing. In the subset of patients who receive neurological care at a MS Center where disease measures have been
collected, we used routinely collected EHR data to extract two aggregate indicators of MS severity of clinical relevance
multiple sclerosis severity score (MSSS) and brain parenchymal fraction (BPF, a measure of whole brain volume).
Results: The EHR algorithm that identifies MS patients has an area under the curve of 0.958, 83% sensitivity, 92% positive
predictive value, and 89% negative predictive value when a 95% specificity threshold is used. The correlation between EHR-
derived and true MSSS has a mean R
2=0.3860.05, and that between EHR-derived and true BPF has a mean R
2=0.2260.08.
To illustrate its clinical relevance, derived MSSS captures the expected difference in disease severity between relapsing-
remitting and progressive MS patients after adjusting for sex, age of symptom onset and disease duration (p=1.56610
212).
Conclusion: Incorporation of sophisticated codified and narrative EHR data accurately identifies MS patients and provides
estimation of a well-accepted indicator of MS severity that is widely used in research settings but not part of the routine
medical records. Similar approaches could be applied to other complex neurological disorders.
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Introduction
With the increasing integration of electronic health records
(EHR) into routine clinical care, there is an emerging interest in
harnessing the wealth of EHR data for clinical research that
ultimately improve patient care. Optimal use of EHR data for
clinical research that would ultimately improve patient outcomes
requires efficient extraction of meaningful information from
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e78927codified data (e.g., demographics, billing codes for diagnoses and
procedures, laboratory results, electronic prescriptions) and
narrative data (e.g., clinical encounter notes, imaging reports) to
accurately identify patient cohorts and measure clinically relevant
outcomes [1,2]. The prevailing approach that relies exclusively on
administrative billing codes can be limited in accuracy and may
miss relevant phenotypes [3]. The growing availability and
functionality of the EHR system together with advances in natural
language processing (NLP) and bioinformatics methods that are
essential for extracting meaningful clinical information from the
EHR data have converged to enable efficient and cost-effective
development of EHR-derived patient cohorts and large-scale
assessment of phenotypes relevant to patient care [1,2,4]. Our
group has built a framework [5,6,7] to successfully leverage EHR
for research in diseases such as asthma [8], depression [9],
inflammatory bowel disease [10], and rheumatoid arthritis
[11,12,13,14]. In parallel, important work led by the Electronic
Medical Records and Genomics (eMERGE) Network has further
demonstrated the broad potential of EHR-based approaches in
discovery and clinical research [15,16,17].
Neurological research leveraging the EHR data is just emerging
[15], in part because the complexity of neurological diseases
creates challenges in deriving relevant disease outcomes not
available from routine clinical encounters. Using multiple sclerosis
(MS) as a proof of principle, we set out to develop a potentially
generalizable informatics approach that would enable EHR
research in neurological diseases. MS typically consists of a
relapsing-remitting inflammatory phase and, in many patients, an
underlying progressive neurodegenerative course that makes this
demyelinating disease of the central nervous system a leading
cause of neurological disability in younger adults [18]. One of the
best predictors of long-term neurological disability in MS is
atrophy on brain magnetic resonance imaging (MRI) [19].
Given that MS patients display heterogeneity in their disease
course and the increasing options for MS treatment have reduced
the number of patients on any specific medication, sample size is
limited for conducting patient-oriented research in MS such as
pharmaco-epidemiology or pharmacogenomic studies. Outcome
data traditionally come from well-designed prospective cohorts,
including the Comprehensive Longitudinal Investigation of MS at
Brigham and Women’s Hospital (CLIMB) [20], which provided
critical data for this study. While EHR-derived cohorts will not
replace clinic or population-based studies, they capture a larger
number of patients and provide unique and complementary
features not found in traditional cohorts. Clinically relevant
outcomes not easily attainable from routine medical records are
crucial for research in EHR-derived cohorts. Here, we report a
rigorous EHR-based informatics approach to (1) accurately
identify MS patients and (2) provide a surrogate measure of
disease severity in MS patients. Our study makes the first step
towards realizing a major goal in personalized medicine:
leveraging each individual’s unique, routinely collected health
information to inform clinical outcome and improve patient care.
Methods
Electronic Health Records Source
The Institutional Review Board of Partners HealthCare
approved all aspects of this study, including the waiver of written
consent for use of de-identified EHR data for research. The
Partners HealthCare EHR system captures nearly five million
patients and contains over one billion clinical observations dating
back to 1994 for the Massachusetts General Hospital and 1996 for
the Brigham and Women’s Hospital, both of which are Harvard-
affiliated teaching hospitals and major tertiary care centers in the
New England area.
EHR Algorithms for Classifying MS
From the Partners HealthCare EHR system, we developed an
EHR-based classification algorithm to identify MS patients (see
Figure 1A for summary of the overall approach). As a first step,
we included any patient with at least one MS-related International
Classification of Disease 9
th edition (ICD-9) code (340, 323 or
341). Using these 22,610 patients, we created an ‘‘MS data mart’’
containing the complete medical records (as of February 2011) of
all their visits to Partners HealthCare sites. Similar to our prior
efforts to identify patients with rheumatoid arthritis and inflam-
matory bowel disease from the EHR system [10,13], we generated
a list of clinician expert-defined, MS-relevant codified and
narrative variables from the EHR data for each patient. Variables
are excluded if the frequency of occurrence in the data mart was
10% or less.
Codified variables were derived from billing codes for diagnoses
and procedures, demographic information and electronic pre-
scriptions. For codified variables, we counted the number of
occurrences per patient (e.g., ICD-9 code for MS, procedure code
for MRI of the brain or cervical spine or orbit, electronic
prescriptions for any of the MS disease-modifying medications).
We also included derivatives of billing codes (e.g., annualized
ICD-9 code for MS, proportion of the total ICD-9 codes in the
EHR belonging to MS).
Narrative variables on symptoms, signs, medications, MRI
reports, and neurologist’s impression and treatment plan were
extracted from free-text clinical narratives (outpatient notes,
discharge summaries, imaging reports and pathology reports)
using the clinical Text Analytics and Knowledge Extraction
System (cTAKES) NLP system (ctakes.apache.org) [21], which
parses the texts to identify clinically relevant concepts and the
associated qualifying attributes (negated, non-negated). Two
neurologists with subspecialty expertise in MS and neuroimmu-
nology created a customized dictionary of MS-relevant terms
based on their clinical experiences and further refined the
dictionary after reviewing 60 randomly selected clinical notes or
imaging reports from known MS patients that were annotated by
cTAKES. Additional MS neurologists reviewed the list of
narrative terms and provided feedback. The refined list of
expert-defined terms were mapped to two health care terminology
indices to allow for language variations: (1) Systematized
Nomenclature of Medicine Clinical Terms (SNOMED-CT)
(http://www.nlm.nih.gov/research/umls/Snomed/
snomed_main.html) serves to organize terms for signs and
symptoms, anatomical sites, disease terms and procedures; (2)
RxNorm (http://www.nlm.nih.gov/research/umls/rxnorm/)
serves to organize terms for generic and brand name medications.
For each narrative variable, we determined the sum of positive and
negative mentions per patient.
Based on an estimation of the number of subjects needed to
develop a classification algorithm, 595 patients from the MS data
mart were randomly selected for a training set to develop the MS-
classifying algorithm. One neurologist reviewed the medical
records of all patients in the training set to establish whether a
patient had a definitive diagnosis of MS, which was supported by
documentation in a neurologist’s clinical note or a relevant MRI
report. We fit LASSO penalized logistic regression models with
Bayesian Information Criterion [22] to select informative EHR
variables for predicting MS diagnosis and estimated their
regression parameters.
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calculated the area under the curve (AUC) using a receiver
operating characteristic analysis as well as sensitivity, positive
predictive value (PPV), and negative predictive value (NPV) at
95% specificity. To correct for overfitting bias, the 0.632 bootstrap
cross-validation was used to obtain bias corrected estimates of all
performance parameters [23]. The standard error estimates were
obtained using a bootstrap procedure with 1,000 replicates. For all
models, we selected a probability threshold corresponding to 95%
specificity and classified patients with a probability exceeding the
threshold value as having a definitive diagnosis of MS. The best
algorithm was then applied to all 22,610 patients in the MS data
mart to assign a probability of definitive MS for each patient and
established an EHR-based cohort of MS patients. From this
cohort, two neurologists reviewed the medical records of 100
randomly selected patients for independent validation of MS
diagnosis.
Multiple Sclerosis Center Patients
A subset of the EHR-derived MS cohort receives neurological
care at the Partners Multiple Sclerosis Center, including patients
who are enrolled in CLIMB, an ongoing prospective natural-
history cohort study [20]. To develop EHR-based algorithms for
brain volume and MS severity, we used the subset of MS patients
with existing brain MRI and clinical outcomes collected prospec-
tively and available from the MS Center database. These
outcomes are collected separately from the EHR data. All patients
met the revised McDonald diagnostic criteria for MS [24]. We
established an interface between the EHR system and the MS
Center database to access data that are not available from routine
Figure 1. Overall approach for developing EHR algorithm to classify multiple sclerosis (A), and to derive surrogate measures of
brain parenchymal fraction and multiple sclerosis severity score in MS patients (B).
doi:10.1371/journal.pone.0078927.g001
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fraction (BPF), the multiple sclerosis severity score (MSSS), and
MS disease category (relapsing-remitting, RR; secondary progres-
sive, SP; primary progressive, PP). Disease outcome data are based
on values collected at each patient’s last available visit as of August
2012. The supplemental text contains details on the neuroimaging
approach and MSSS measure.
Neuroimaging approach has been described in detail elsewhere
[25,26,27]. Briefly, dual-echo proton density and T2-weighted
axial images of 3-mm thick sections from routine clinical brain
MRI scans on a 1.5 Tesla system were segmented using a semi-
automated pipeline. MRI scans underwent quality control with
manual correction of detected tissue misclassification to provide
corrected BPF. For each patient, only the corrected BPF measure
from the most recent brain MRI scan was used for algorithm
development.
MSSS is a method for quantifying MS disease severity in the
course of MS, based on a single assessment of a clinical indicator of
MS disability known as the Kurtzke Expanded Disability Status
Scale (EDSS) score, adjusted for disease duration [28]. Disease
duration is defined as the time interval from the self-reported
symptom onset to the recorded clinic encounter. Using EDSS and
disease duration from the most recent clinic visit, we calculated the
MSSS for each patient. We excluded any EDSS measures
captured within the first two years of symptom onset, given that
MSSS is not robust at this stage of the disease.
EHR Algorithms for Deriving Brain Volume and Disease
Severity in MS
Using a list of expert-defined EHR variables (Table S1) and
existing brain MRI and clinical features, we develop algorithms for
brain volume and MS disease severity. We included all patients
with available BPF and MSSS after 2004 to maximize sample size.
To reduce the confounding effects of race and ethnicity, which
influence disease course [29], we only included patients with self-
reported European ancestry (representing approximately 90% of
the patients in the MS Center, n=789 for BPF, n=1,835 for
MSSS).
To develop EHR algorithms for BPF and MSSS, we took a
double cross-validation approach (Figure 1B). Subjects are
divided into a training (50%), test (30%) and validation (20%)
subgroup. In the training set, we performed a 5-fold cross-validated
stepwise regression to select EHR variables to be included in the
algorithms. To avoid over-fitting the algorithms in the training set,
we determined, in the independent test set, the magnitude of the
beta coefficient (or the weight) of each EHR variable selected from
the training set, to create the final algorithms. We applied the
algorithms to the independent validation set to assess algorithm
performance as measured by the correlation between algorithm-
derived and corresponding known outcome (either BPF or MSSS)
using R
2 adjusted for the number of variables. The entire process,
starting with dividing the subjects into test, training and validation
set, was repeated 100 times to obtain the mean R
2 for the BPF and
MSSS algorithms.
EHR variables that had a non-zero value in ,10% subjects
were removed. In addition to EHR variables, we evaluated the
algorithm performance when considering the following variables
that are obtained from the MS Center database: age at first
symptom, sex and disease duration for BPF, and age at first
symptom and sex for MSSS. The details of determining the
optimal frequency threshold for the EHR variables are described
in the text S1 (Table S2, Figure S3).
Results
Establishing EHR-based MS Cohort
Our approach to identify an EHR-derived cohort of MS
patients is summarized in Figure 1A. Performance of the MS
classifying algorithms at 95% specificity is presented in Table 1.
The algorithm that includes both codified and NLP-extracted
narrative variables (Figure S1, Table S3) showed the best
performance and accurately identified MS patients with an area
under the curve (AUC) of 0.95860.006 on a receiver-operator
characteristics analysis (Figure S2). Setting the false positive rate
or specificity at 95%, this combined algorithm had a sensitivity of
82.762.4%, positive predictive value (PPV) of 92.160.6% and
negative predictive value (NPV) of 88.861.7%. The algorithm
containing both codified and narrative variables exhibited superior
performance (better sensitivity, PPV, NPV and accuracy) when
compared with the other three versions of the MS classification
algorithm: the model based only on the MS ICD-9 code (the
prevailing approach), the codified data-only model and the NLP
data-only model (Table 1).
We applied the combined algorithm to the pool of 22,610
patients with at least one MS-related ICD-9 code in the Partners
Healthcare EHR system and identified 5,495 MS patients at 95%
specificity as the EHR-based MS cohort for the remainder of the
study (see Table 2 for demographics). Consistent with the
sensitivity of the algorithm, this MS virtual cohort captured
85.5% of the MS subjects who are registered in the Partners MS
Center database.
To address whether EHR data can be harnessed to provide
clinically meaningful phenotypes, we studied a subset of the MS
patients in the EHR-derived cohort who receive neurological care
at an MS Center (‘‘clinical cohort’’). From the MS Center
database, we obtained two types of MS disease course data that
have been prospectively collected but are not available in routine
medical records: (1) brain parenchymal fraction (BPF), a measure
of whole brain volume derived from semi-automated segmentation
of brain MRI scans with manual correction, (2) multiple sclerosis
severity score (MSSS), a measure of disease severity and disability
adjusted for disease duration.
Table 1. Performance of the four models of the EHR
algorithm for identifying multiple sclerosis patients (at 95%
specificity).
Model
a
Sensitivity
(SE) PPV (SE) NPV (SE) AUC (SE)
ICD 0.600 (0.058) 0.894 (0.013) 0.769 (0.029) 0.890 (0.013)
COD 0.764 (0.038) 0.916 (0.007) 0.849 (0.023) 0.937 (0.010)
NLP 0.758 (0.034) 0.914 (0.006) 0.849 (0.021) 0.941 (0.008)
ALL 0.827 (0.024) 0.921 (0.006) 0.888 (0.017) 0.958 (0.006)
aThe ICD model uses the number of ICD-9 code for MS as the only variable. The
Codified (COD) model includes codified variables in addition to the number of
ICD-9 code for MS. The NLP model includes narrative variables extracted from
clinical texts. The combined (ALL) model uses both codified and narrative
variables. Performance parameters are calculated using 0.632 bootstrap cross-
validation in the training set. The standard errors are estimated based on 1,000
bootstrap replications.
Abbreviations: AUC, area under the curve; NPV, negative predictive value; PPV,
positive predictive value; SE, standard error of the estimates.
doi:10.1371/journal.pone.0078927.t001
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To derive a surrogate measure of whole brain volume in our
MS patients, we used patients of European ancestry who have at
least one measure of manually corrected BPF (n=789) collected in
the clinical cohort study. Figure 1B summarizes our double cross-
validation approach to develop the BPF algorithm in the training
and test sets. We then assessed its performance in the validation
set. Figure 2A shows the correlation between the derived BPF
and the true BPF in each set of subjects. As expected, the
correlation (R
2) is the best in the training set where it is over-fitted.
The correlation in the validation set is the most accurate
assessment of the algorithm’s performance as it is applied to an
independent subset of subjects. We repeated this algorithm
building process 100 times, permuting the assignment of subjects
to each set and creating a distribution of R
2 values for each set.
The mean value for each set is reported. The BPF algorithm in the
validation sets has an adjusted mean R
2 of 0.2260.08.
The algorithm for deriving BPF contains both codified and
narrative EHR variables (Figure S4A, Table S4). In addition,
the clinical cohort database provided the variables of age at
symptom onset and disease duration at the time of MRI since
these variables are known to correlate with brain volume [19,30]
but not available in routine medical records. The performance of
the BPF algorithm in the validation set is reduced from a mean R
2
of 0.2260.08 to 0.0160.04 when only codified variables are
included and to 0.000760.09 when only narrative variables are
included in the algorithm. Thus, neither type of EHR data alone is
sufficient to produce an estimate of BPF. When the BPF algorithm
includes only sex, age of symptom onset and disease duration, it
has a mean R
2 of 0.2860.06, suggesting that the existing EHR
variables are not informative for deriving a surrogate measure of
BPF.
Deriving MS Severity Score from EHR Data
We used the same approach to develop an EHR algorithm that
derives a surrogate measure of MS severity in patients of European
ancestry within the EHR-based cohort who have at least one
Multiple Sclerosis Severity Score (MSSS, n=1835) (Figure 1B).
Following the double cross-validation approach, the correlation
between the derived and true MSSS in the independent validation
sets had an adjusted mean R
2 of 0.3860.05 (Figure 2B).
Because the algorithm for deriving MSSS also contains both
codified and narrative variables from the EHR as well as sex and
age of symptom onset from the clinical cohort database (Figure
S4B, Table S5), we assessed the contribution of the different
types of variables. (MSSS already accounts for disease duration.)
The performance of the MSSS algorithm in the validation set was
reduced from an adjusted mean R
2 of 0.3860.05 to 0.1660.06
when only codified variables are included and to 0.3160.06 when
only narrative variables are included in the algorithm. Thus, the
NLP-extracted narrative data are highly informative in the MSSS
algorithm. When the MSSS algorithm included only sex and age
of symptom onset, it has a mean R
2 of 0.0560.02, further
confirming that the EHR variables are necessary for deriving
MSSS.
Distribution of EHR-derived MSSS in Relapsing-Remitting
and Progressive MS Patients
To illustrate the validity of EHR-derived measures of MSSS, we
tested whether we could reproduce the known differences in
MSSS measures observed between relapsing-remitting and pro-
gressive MS patients. Based on published reports [31] and
observations from our own Partners MS Center, progressive MS
patients are known to have, on average, more disability than
relapsing-remitting MS patients after adjusting for age and disease
duration. Among the MS patients within the EHR-based cohort
with both BPF and MSSS measures and known disease categories
from the MS Center database at the time of the measures
(n=542), 59 are primary progressive or secondary progressive,
and 483 are relapsing-remitting. We divided these patients into a
discovery and replication set and compared the difference in
observed and derived MSSS between progressive and relapsing-
remitting patients in both sets (Table 3). After considering the
differences in sex, age of symptom onset and disease duration,
primary and secondary progressive MS patients have a higher
mean EHR-derived MSSS than relapsing-remitting MS patients
Table 2. Characteristics of the EHR-derived cohort of multiple sclerosis (MS) patients and the subset of patients who receive care
at a subspecialty MS Center
a.
Parameter EHR-derived Cohort (n=5,495) MS Center Subset (n=4,241)
Sex (% female) 73% 73%
Race/Ethnicity (% non-Hispanic white) 72% 75%
Age at first ICD-9 code for MS, years (median [Q1–Q3]) 41 [33–49] 40 [32–49]
Duration of follow-up, years (median [Q1–Q3]) 8.4 [3.5–13.7] 9.1 [4.3–14.4]
Number of ICD-9 code for MS per patient (median [Q1–Q3]) 22 [8–49] 26 [9–55]
Number of MRI brain per patient (median [Q1–Q3]) 6 [3–12] 8 [4–14]
Number of MRI cervical spine per patient (median [Q1–Q3]) 4 [2–6] 4 [2–7]
Number of entries by a MS neurologist per patient
(median [Q1–Q3])
47 [13–124] 56 [12–139]
Number of prescriptions for MS disease modifying
treatment per patient (median [Q1–Q3])
5 (2–13) 6 (3–15)
Receiving MS disease modifying treatment, % 49% 55%
aA subset of the patients in the EHR-derived MS cohort receives neurological care at the Partners MS Center where neuroimaging and clinical outcomes are available.
For comparison, our cohort shares similar basic demographic characteristics as an independent MS patient registry from the North American Research Committee on
Multiple Sclerosis (NARCOMS): 73% of the NARCOMS patients are female, 90% are self-described White, mean age at diagnosis is 37 years, and 52% of the patients are
receiving immune modulatory therapy [32].
Abbreviation: ICD-9=340 is the diagnostic code for MS.
doi:10.1371/journal.pone.0078927.t002
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PLOS ONE | www.plosone.org 5 November 2013 | Volume 8 | Issue 11 | e78927Figure 2. Density distribution of the performance (adjusted R
2) of the EHR algorithm for deriving brain parenchymal fraction (A),
and multiple sclerosis severity score (B). Performance is measured as variance that explains the correlation between the derived and true
outcomes after adjusting for the number of variables in the model.
doi:10.1371/journal.pone.0078927.g002
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223; and replication, p=1.56610
212),
consistent with observations based on actual MSSS (Table 3).
Discussion
Using a medical informatics framework and rigorous statistical
methodology, our study showcases an approach that begins to
harness routine EHR data for accurate identification of patients
with a complex neurologic disease and for deriving a highly
relevant clinical outcome heretofore only available in research
studies. Specifically, our study leverages the EHR data of a large
cohort of MS patients to provide the Multiple Sclerosis Severity
Score, an important indicator of disease severity that is not part of
routine medical records. Although the derived MSSS measure is
not yet robust for research, this approach provides the first steps
towards harnessing existing EHR data for patient-oriented
research in neurological diseases that will enable exploration of
the many unique features of the EHR data as EHR systems
become widely adopted across the health care landscape.
Our approach embraces the rich complexity of the EHR data.
The incorporation of sophisticated codified data and NLP-
extracted narrative data improved the performance of the EHR
algorithm to identify MS patients when compared to the approach
relying only on ICD-9 codes. With this approach, we established a
cohort of 5,495 MS patients, including a subset that is part of a
patient cohort based at MS Center. This unique ‘‘virtual cohort’’
enables analyses that integrate the new EHR-derived variables
with traditional clinical research data. Further, we demonstrated
that NLP-extracted narrative data are necessary for generating an
informative estimate for MSSS. As a demonstration of its clinical
relevance, EHR-derived MSSS captures the difference between
the two main subgroups of MS patients: relapsing-remitting
patients who generally recover neurological function after a
relapse and progressive patients who experience decline in
function. With future improvement in EHR data and informatics
methods, we will enhance the MSSS algorithm (to reach at least
R=0.8) so that this surrogate measure may be potentially
integrated into the EHR system to allow better monitor of patient
outcomes and for research.
EHR data did not contribute meaningfully to the performance
of the BPF algorithm, which can be almost entirely explained by
variables obtained from the clinical cohort database: age of first
symptom and disease duration. This illustrates the limitation that
EHR variables considered here are not sufficient to inform every
pertinent outcome measure. To provide a surrogate of brain
volume, critical information to supplement EHR data can be
obtained using questionnaires to ascertain age of symptom onset
and disease duration. Thus, integration of EHR data and data
from clinical research tools such as questionnaires provides a path
for future investigations that leverage the strengths of both
approaches. Brain volume is not routinely measured in clinical
care, but it is correlated with disease course and is an important
research measure in MS. Surrogate measures of brain volume
derived from these combined approaches could enable the
exploration of hypotheses that cannot be effectively investigated
at smaller sample sizes, despite the use of more accurate measures.
In the future, we plan to enhance the algorithm development for
whole brain volume by applying automated feature selection
methods to the entire narrative text based on the medical ontology
systems such as SNOMED-CT instead of only expert-selected
EHR variables. Further, disease duration may be derived if the
date of the first neurological symptom can be captured by more
sophisticated NLP capability.
Our study has two other limitations. First, our algorithms for
MS were developed and tested within a single EHR system that
links two major tertiary care hospitals and affiliates. We have not
yet tested the portability of our algorithms. This is an important
next step, as we will seek replication of the EHR algorithms for
classifying MS and deriving MS disease outcomes in the EHR
systems of other healthcare institutions. If proven portable, this
approach promises efficient and cost-effective development of
multi-center cohorts to address research questions highly relevant
to neurological patients. It is reassuring that our group has
developed a similar EHR algorithm for classifying rheumatoid
arthritis and demonstrated its portability in two other academic
medical centers with limited retraining of the algorithm [11].
The second limitation involves our current inability to finely
dissect the temporal relationship between the EHR data and
indicators of MS disease severity. Specifically, the EHR data used
for algorithm development represent aggregate information as of
the time of the MS data mart creation, and the latest available
measures of BPF and MSSS from the MS Center clinical cohort
do not necessarily occur after the aggregate information has been
collected. Thus, our study demonstrated cross-sectional associa-
tions and should not be construed as predictive algorithms as this
would imply that the EHR data occurred before the BPF or MSSS
measures. As medical informatics technologies continue to
improve the parsing of temporal relationships, truly predictive
algorithms for brain volume and disease severity will emerge and
be translated into the clinical arena to guide patient management.
Table 3. EHR-derived MS severity score (MSSS) captures the difference between progressive MS and relapsing-remitting MS
patients.
Discovery Set
b (n=329) Validation Set
b (n=213)
Outcome
a
PPMS/SPMS (n=34)
Mean (SE)
RRMS (n=295)
Mean (SE) p-value
PPMS/SPMS(n=25)
Mean (SE)
RRMS (n=188)
Mean (SE) p-value
Observed MSSS 3.86 (0.27) 0.86 (0.10) 1.55E-23 4.36 (0.29) 0.73 (0.11) 3.32E-26
Derived MSSS 2.90 (0.18) 0.98 (0.06) 9.42E-23 3.22 (0.18) 1.10 (0.07) 1.56E-12
aObserved MSSS is based on actual data from MS patients who receive care at the Partners MS Center. Derived MSSS is based on algorithm with 40% frequency cut-off
for EHR variables.
bPatients with known MS disease category were divided into a discovery set (n=329, including 34 PPMS/SPMS patients and 295 RRMS patients) and a validation set
(n=213, including 25 PPMS/SPMS and RRMS patients). For the observed measure of MSSS, ANOVA was performed and the comparison was adjusted for sex, age of
symptom onset and disease duration as covariates. For derived surrogate measure of MSSS, t-test was performed. The effects of sex, age of symptom onset, and disease
duration are accounted for in the derivation of the surrogate measure of MSSS.
Abbreviations: BPF, brain parenchymal fraction; MSSS, multiple sclerosis severity score; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple
sclerosis; SPMS, secondary progressive multiple sclerosis.
doi:10.1371/journal.pone.0078927.t003
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PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e78927In the age of personalized medicine, EHR data provide another
complementary layer of biomedical data. The challenge is to
integrate EHR data with other data to improve patient care. Our
study in MS showcases an informatics approach that harnesses
routine EHR data to derive MSSS, a well-accepted and clinically
meaningful disease measure heretofore available only in research
studies. If replicated, our novel informatics approach will enable
the development of multi-center cohorts and facilitate testing of a
variety of new hypotheses leveraging the unique features of the
EHR data to address MS disease activity, comorbidities, treatment
response and presymptomatic disease. These efforts also hold the
promise of establishing automated monitors of an individual
patient’s disease trajectory using EHR and aiding clinician’s task of
delivering more individualized patient management. Finally, while
MS was used as a proof of principle in this study, our approach has
the potential of being applied in other complex neurological
diseases.
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